Cognition Therapeutics, Inc.

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio

Pyxis Oncology , Theseus Pharmaceuticals, Inc. and Cognition Therapeutics, Inc. launched initial public offerings in the US between 6 and 8 October, raising $373.2m combined, but the first three c